RPP25 and systemic sclerosis: Further studies using large cohorts of SSc patients such as those collected by EULAR Scleroderma Trials and Research (EUSTAR) [35], the Canadian Scleroderma Research Group (CSRG) [36] or the German Network for systemic scleroderma [13] and the Australian cohort [37] are needed to analyze the clinical utility of antibodies to Rpp25.